Pluristem Therapeutics (NASDAQ: PSTI) has completed development of its second major product line, and can now begin manufacturing the cells ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE